zoldonrasib
zoldonrasib: sourced relationships with 1 company · 8 clinical trials tracked.
zoldonrasib evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could zoldonrasib → RVMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| REVOLUTION MEDICINES, INC. (RVMD) Pancreatic Cancer; Advanced Solid Tumors; NSCLC | Phase 3 |
Clinical Trial Registry Records (8)
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)
Primary endpoint: Progression free survival (PFS)
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
Primary endpoint: Phase 1: Maximum Tolerated Dose
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Primary endpoint: Adverse events (Subprotocols A-F)
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Primary endpoint: Adverse events
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
Primary endpoint: Adverse events
Frequently asked questions
Which companies have sourced relationships with zoldonrasib?
zoldonrasib has dated SEC/FDA relationship records for REVOLUTION MEDICINES, INC..
How many clinical trials involve zoldonrasib?
BioSniper tracks 8 clinical trials involving zoldonrasib.